Industry News
Genetically engineered TCR-T lead to target solid tumors
Zelluna Immunotherapy presented data on its lead compound ZI-H04 at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
News & Articles
25
Zelluna Immunotherapy presented data on its lead compound ZI-H04 at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC)